Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Crispr Therapeutics participates in a conference call with Morgan Stanley » 16:00
09/25/20
09/25
16:00
09/25/20
16:00
CRSP

Crispr Therapeutics

$84.02 /

+0.83 (+1.00%)

Australian Lead…

Australian Lead Healthcare Analyst Laman holds a conference call with CEO Kulkami on September 28 at 6 pm hosted by Morgan Stanley.

ShowHide Related Items >><<
CRSP Crispr Therapeutics
$84.02 /

+0.83 (+1.00%)

CRSP Crispr Therapeutics
$84.02 /

+0.83 (+1.00%)

09/22/20 Piper Sandler
Crispr Therapeutics remains a top pick at Piper Sandler
08/05/20 Citi
Citi reiterates Sell rating on Crispr Therapeutics with $31 price target
07/28/20 Needham
Crispr Therapeutics price target raised to $105 from $84 at Needham
07/28/20 Wells Fargo
Crispr Therapeutics price target raised to $110 from $95 at Wells Fargo
CRSP Crispr Therapeutics
$84.02 /

+0.83 (+1.00%)

  • 01
    Jul
  • 21
    Nov
CRSP Crispr Therapeutics
$84.02 /

+0.83 (+1.00%)

Thursday
Hot Stocks
Calithera Biosciences initiates KEAPSAKE Phase 2 trial of telaglenastat » 07:13
09/24/20
09/24
07:13
09/24/20
07:13
CALA

Calithera Biosciences

$3.44 /

-0.195 (-5.37%)

Calithera Biosciences…

Calithera Biosciences announced treatment of the first patient in a randomized Phase 2 non-small cell lung cancer clinical trial of the glutaminase inhibitor telaglenastat in combination with pembrolizumab, carboplatin and pemetrexed. The KEAPSAKE study will evaluate the safety and anti-tumor activity of telaglenastat plus standard-of-care immunotherapy as front-line therapy among patients with stage IV non-squamous NSCLC whose tumors have a KEAP1 or NRF2 mutation determined by next-generation sequencing. Mutations in the KEAP1/NRF2 pathway, which occur in an estimated 20 percent of NSCLC patients, are associated with aggressive tumor growth. Recently presented clinical data demonstrate that activation of this pathway, either through the loss of KEAP1 function or activation of NRF2, are associated with poor clinical outcomes among patients with NSCLC receiving front-line standard-of-care chemoimmunotherapy. Pre-clinical models have shown that activation of the KEAP1/NRF2 pathway results in dependence on glutaminase activity for growth and survival, making these tumors exquisitely sensitive to inhibition of glutaminase activity by telaglenastat. The double-blind KEAPSAKE trial will enroll approximately 120 patients with stage IV non-squamous NSCLC with tumors that have the KEAP1 or NRF2 mutation. Patients will be randomized to receive telaglenastat or placebo, in combination with pembrolizumab, carboplatin and pemetrexed. The study will evaluate the safety and investigator-assessed progression-free survival of telaglenastat plus this standard-of-care chemoimmunotherapy regimen. Guardant360 liquid biopsy test will be provided by the study sponsor as an investigational use only testing option for patient selection. Calithera anticipates sharing interim data from the KEAPSAKE trial in 2021.

ShowHide Related Items >><<
CALA Calithera Biosciences
$3.44 /

-0.195 (-5.37%)

CALA Calithera Biosciences
$3.44 /

-0.195 (-5.37%)

05/11/20 Citi
Calithera Biosciences price target raised to $10 from $7 at Citi
05/08/20 H.C. Wainwright
Calithera Biosciences price target raised to $9.50 from $7 at H.C. Wainwright
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Jefferies
Jefferies starts Calithera at Buy ahead of three data catalysts
CALA Calithera Biosciences
$3.44 /

-0.195 (-5.37%)

  • 16
    Apr
CALA Calithera Biosciences
$3.44 /

-0.195 (-5.37%)

Hot Stocks
Axsome Therapeutics' AXS-07 shows effective migraine relief in Phase 3 trial » 06:04
09/24/20
09/24
06:04
09/24/20
06:04
AXSM

Axsome Therapeutics

$77.77 /

-3.52 (-4.33%)

Axsome Therapeutics'…

Axsome Therapeutics' oral, multi-mechanistic investigational medicine for the acute treatment of migraine, AXS-07, relieved and substantially reduced relapse of migraine pain, as compared to the potent active comparator rizatriptan, in the MOMENTUM Phase 3 trial. These findings were presented at the live sessions of the 2020 American Academy of Neurology Science Highlights platform held virtually September 23-24. The MOMENTUM study enrolled only patients with a history of inadequate response to prior acute migraine treatments. A total of 1,594 patients were randomized to treat a single migraine attack of moderate or severe intensity. AXS-07 demonstrated faster and more durable relief of migraine pain as compared to rizatriptan. The probability of achieving pain relief with AXS-07 was greater than with rizatriptan within 30 minutes after dosing and at every time point thereafter, with a median time to migraine pain relief that was nearly 3x faster for AXS-07 compared to rizatriptan. AXS-07 substantially and significantly reduced relapse of migraine pain as compared to rizatriptan, with 45.2% of rizatriptan-treated patients experiencing relapse compared to 21.2% of AXS-07 patients over 48 hours after dosing. AXS-07 met both co-primary endpoints of the trial by demonstrating a greater percentage of patients achieving pain freedom and absence of most bothersome symptom, 2 hours after dosing, as compared to placebo. AXS-07 was safe and well tolerated in the trial. The most commonly reported adverse events with AXS-07 were nausea, dizziness and somnolence, none of which occurred at a rate greater than placebo or greater than 3%. AXS-07 is covered by 44 issued U.S. and international patents providing protection out to 2036, and Axsome maintains worldwide rights.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$77.77 /

-3.52 (-4.33%)

AXSM Axsome Therapeutics
$77.77 /

-3.52 (-4.33%)

09/10/20 Morgan Stanley
Axsome Therapeutics initiated with an Overweight at Morgan Stanley
09/01/20 Guggenheim
Axsome's Alzheimer's agitation update better than expected, says Guggenheim
07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
AXSM Axsome Therapeutics
$77.77 /

-3.52 (-4.33%)

  • 19
    Dec
AXSM Axsome Therapeutics
$77.77 /

-3.52 (-4.33%)

AXSM Axsome Therapeutics
$77.77 /

-3.52 (-4.33%)

Conference/Events
Autolus Therapeutics management to meet virtually with Truist » 04:55
09/24/20
09/24
04:55
09/24/20
04:55
AUTL

Autolus Therapeutics

$12.66 /

-0.63 (-4.74%)

Virtual Meeting to be…

Virtual Meeting to be held on September 24 hosted by Truist.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$12.66 /

-0.63 (-4.74%)

AUTL Autolus Therapeutics
$12.66 /

-0.63 (-4.74%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
AUTL Autolus Therapeutics
$12.66 /

-0.63 (-4.74%)

  • 23
    Jan
Wednesday
Conference/Events
Global Blood Therapeutics participates in a conference call with JPMorgan » 13:25
09/23/20
09/23
13:25
09/23/20
13:25
GBT

Global Blood Therapeutics

$54.71 /

+1.2 (+2.24%)

Large Cap Biotech Analyst…

Large Cap Biotech Analyst Holt holds a conference call with CEO Love, CFO Farrow and CCO Johnson on September 23 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$54.71 /

+1.2 (+2.24%)

GBT Global Blood Therapeutics
$54.71 /

+1.2 (+2.24%)

09/14/20 Guggenheim
Guggenheim says Global Blood COVID case supports transfusion sparing potential
08/25/20 Wedbush
Global Blood Therapeutics price target raised to $152 from $145 at Wedbush
08/24/20 Raymond James
Global Blood Therapeutics initiated with an Outperform at Raymond James
07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
GBT Global Blood Therapeutics
$54.71 /

+1.2 (+2.24%)

On The Fly
Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock » 12:10
09/23/20
09/23
12:10
09/23/20
12:10
NVS

Novartis

$88.10 /

-0.77 (-0.87%)

, RGNX

Regenxbio

$28.28 /

-0.59 (-2.04%)

, IONS

Ionis Pharmaceuticals

$50.11 /

-0.63 (-1.24%)

, BIIB

Biogen

$275.85 /

+3.07 (+1.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, PTCT

PTC Therapeutics

$46.18 /

+0.06 (+0.13%)

Shares of Regenxbio…

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
$28.28 /

-0.59 (-2.04%)

PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

IONS Ionis Pharmaceuticals
$50.11 /

-0.63 (-1.24%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
09/10/20 UBS
Novartis upgraded to Buy from Neutral at UBS
RGNX Regenxbio
$28.28 /

-0.59 (-2.04%)

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/25/20 BofA
Regenxbio reinstated with a Buy at BofA
05/12/20 RBC Capital
Regenxbio initiated with a Sector Perform at RBC Capital
IONS Ionis Pharmaceuticals
$50.11 /

-0.63 (-1.24%)

09/22/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target raised to $59 from $56 at Cantor Fitzgerald
09/14/20 JPMorgan
Ionis Pharmaceuticals resumed with a Neutral at JPMorgan
BIIB Biogen
$275.85 /

+3.07 (+1.13%)

09/18/20 RBC Capital
Biogen price target lowered to $277 from $284 at RBC Capital
09/17/20 Morgan Stanley
Court ruling eliminates hurdle for Tecfidera generics, says Morgan Stanley
09/16/20 Raymond James
Mylan exclusivity on Tecfidera generic abruptly ending, says Raymond James
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

08/24/20 Raymond James
PTC Therapeutics initiated with an Outperform at Raymond James
08/11/20 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $85 at Cantor Fitzgerald
07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
$28.28 /

-0.59 (-2.04%)

PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

IONS Ionis Pharmaceuticals
$50.11 /

-0.63 (-1.24%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$46.18 /

+0.06 (+0.13%)

NVS Novartis
$88.10 /

-0.77 (-0.87%)

IONS Ionis Pharmaceuticals
$50.11 /

-0.63 (-1.24%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

BIIB Biogen
$275.85 /

+3.07 (+1.13%)

Conference/Events
Autolus Therapeutics management to meet virtually with Truist » 11:21
09/23/20
09/23
11:21
09/23/20
11:21
AUTL

Autolus Therapeutics

$12.92 /

-0.37 (-2.78%)

Virtual Meeting to be…

Virtual Meeting to be held on September 24 hosted by Truist.

ShowHide Related Items >><<
AUTL Autolus Therapeutics
$12.92 /

-0.37 (-2.78%)

AUTL Autolus Therapeutics
$12.92 /

-0.37 (-2.78%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
07/31/20
Fly Intel: Top five analyst initiations
07/31/20 JPMorgan
Autolus Therapeutics initiated with an Overweight at JPMorgan
07/22/20 Truist
Autolus Therapeutics initiated with a Buy at SunTrust
AUTL Autolus Therapeutics
$12.92 /

-0.37 (-2.78%)

  • 23
    Jan
Conference/Events
Global Blood Therapeutics participates in a conference call with JPMorgan » 10:33
09/23/20
09/23
10:33
09/23/20
10:33
GBT

Global Blood Therapeutics

$53.22 /

-0.29 (-0.54%)

Large Cap Biotech Analyst…

Large Cap Biotech Analyst Holt holds a conference call with CEO Love, CFO Farrow and CCO Johnson on September 23 at 2 pm hosted by JPMorgan.

ShowHide Related Items >><<
GBT Global Blood Therapeutics
$53.22 /

-0.29 (-0.54%)

GBT Global Blood Therapeutics
$53.22 /

-0.29 (-0.54%)

09/14/20 Guggenheim
Guggenheim says Global Blood COVID case supports transfusion sparing potential
08/25/20 Wedbush
Global Blood Therapeutics price target raised to $152 from $145 at Wedbush
08/24/20 Raymond James
Global Blood Therapeutics initiated with an Outperform at Raymond James
07/20/20 Roth Capital
Global Blood Therapeutics initiated with a Buy at Roth Capital
GBT Global Blood Therapeutics
$53.22 /

-0.29 (-0.54%)

Recommendations
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO » 09:34
09/23/20
09/23
09:34
09/23/20
09:34
IONS

Ionis Pharmaceuticals

$50.74 /

+0.53 (+1.06%)

, NVS

Novartis

$88.87 /

-0.65 (-0.73%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim keeps his Outperform rating and $86 price target on Ionis Pharmaceuticals (IONS) after the delay to Novartis (NVS) AVXS-101 following FDA feedback after review of data in older SMA Type 2 patients. The delay is a positive for Ionis' Spinraza, pushing out additional competition in the larger late onset population and potential launch beyond 2023, the analyst tells investors in a research note.

ShowHide Related Items >><<
NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/22/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target raised to $59 from $56 at Cantor Fitzgerald
09/14/20 JPMorgan
Ionis Pharmaceuticals resumed with a Neutral at JPMorgan
09/08/20 Citi
Ionis Pharmaceuticals price target lowered to $74 from $78 at Citi
NVS Novartis
$88.87 /

-0.65 (-0.73%)

09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
09/10/20 UBS
Novartis upgraded to Buy from Neutral at UBS
09/01/20 Morgan Stanley
Novartis upgraded to Overweight from Equal Weight at Morgan Stanley
NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

Recommendations
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink » 09:13
09/23/20
09/23
09:13
09/23/20
09:13
RGNX

Regenxbio

/

+

, NVS

Novartis

$88.87 /

-0.65 (-0.73%)

, IONS

Ionis Pharmaceuticals

$50.74 /

+0.53 (+1.06%)

, BIIB

Biogen

$272.65 /

+4.34 (+1.62%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, PTCT

PTC Therapeutics

$46.12 /

+0.64 (+1.41%)

SVB Leerink notes that…

SVB Leerink notes that Regenxbio (RGNX) partner Novartis (NVS) indicated that the FDA has requested a confirmatory pivotal study for the regulatory submission of intrathecal Zolgensma in Spinal Muscular Atrophy. The firm estimates that this additional pivotal study, intended to supplement data from the STRONG study, will cause a 2-year delay to launch of intrathecal Zolgensma from previous estimates of approval in early 2022. The confirmatory trial requirement is unrelated to the partial clinical hold, which remains in place and could delay the confirmatory study initiation and enrollment, potentially pushing the launch out further. SVB Leerink believes these developments are a meaningful positive for Ionis Pharmaceuticals (IONS)/Biogen (BIIB) Spinraza and Roche (RHHBY)/PTC Therapeutics' (PTCT) risdiplam as they limit competition in older SMA patients to these two agents, and a painful negative for Regenxbio, with limited years of life remaining in the patents underlying the royalty stream on Zolgensma. The firm expects Ionis shares to trade up in relief and Regenxbio shares to be down sharply.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
/

+

PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

RGNX Regenxbio
/

+

08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/25/20 BofA
Regenxbio reinstated with a Buy at BofA
05/12/20 RBC Capital
Regenxbio initiated with a Sector Perform at RBC Capital
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
NVS Novartis
$88.87 /

-0.65 (-0.73%)

09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
09/10/20 UBS
Novartis upgraded to Buy from Neutral at UBS
09/01/20 Morgan Stanley
Novartis upgraded to Overweight from Equal Weight at Morgan Stanley
08/27/20 Piper Sandler
Intercept's OCA 'comes out on top' at EASL, says Piper Sandler
IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

09/22/20 Cantor Fitzgerald
Ionis Pharmaceuticals price target raised to $59 from $56 at Cantor Fitzgerald
09/14/20 JPMorgan
Ionis Pharmaceuticals resumed with a Neutral at JPMorgan
09/08/20 Citi
Ionis Pharmaceuticals price target lowered to $74 from $78 at Citi
09/02/20 Benchmark
Benchmark starts Ionis at Hold, cautious on Spinraza competition
BIIB Biogen
$272.65 /

+4.34 (+1.62%)

09/18/20 RBC Capital
Biogen price target lowered to $277 from $284 at RBC Capital
09/17/20 Morgan Stanley
Court ruling eliminates hurdle for Tecfidera generics, says Morgan Stanley
09/16/20 Raymond James
Mylan exclusivity on Tecfidera generic abruptly ending, says Raymond James
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

08/24/20 Raymond James
PTC Therapeutics initiated with an Outperform at Raymond James
08/11/20 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $85 at Cantor Fitzgerald
07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
RHHBY Roche
$0.00 /

+ (+0.00%)

RGNX Regenxbio
/

+

PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PTCT PTC Therapeutics
$46.12 /

+0.64 (+1.41%)

NVS Novartis
$88.87 /

-0.65 (-0.73%)

IONS Ionis Pharmaceuticals
$50.74 /

+0.53 (+1.06%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

BIIB Biogen
$272.65 /

+4.34 (+1.62%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.